Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled AQ001S (Budesonide) for Acute COVID-19
NCT05000346Phase 2Terminated
- Sponsor
- Aquilon Pharma
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of budesonide in coronavirus disease 2019 (COVID-19), sponsored by Aquilon Pharma. Started Nov 2021; status: terminated.
02
Drugs
budesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05000346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000346.